A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT
Conclusions: The efficacy data of FAS are consistent with the efficacy results of published phase III clinical trials in IPF. Approximately one third of IPF patients treated with pirfenidone in real-life settings were still under treatment 2 years after initiation. Safety data are consistent with the known safety profile of pirfenidone.Respiration
Source: Respiration - Category: Respiratory Medicine Source Type: research
More News: Clinical Trials | Drugs & Pharmacology | France Health | Hypertension | Pulmonary Hypertension | Respiratory Medicine | Study